Meeting
2021 ASCO Annual Meeting
Engineered immunostimulatory cells can convert PBMCs from chronic lymphocytic leukemia (CLL) patients into potent tumor killing immune cells.
Authors
Joshua W. Keegan
Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Joshua W. Keegan , Frank Borriello , Stacey M. Fernandes , Jennifer R. Brown , James A. Lederer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Chronic Lymphocytic Leukemia (CLL) and Hairy Cell
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 7517)
DOI
10.1200/JCO.2021.39.15_suppl.7517
Abstract #
7517
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Effect of camelid B7-H3 tri-specific killer engagers on natural killer cells in patients with prostate cancer.
First Author: Nicholas Zorko
Poster
2024 ASCO Genitourinary Cancers Symposium
Effect of combined treatment with sipuleucel-T and IL-15 on tumor control, tumor-infiltrating immune effectors, and key mediators of immunoresistance in a preclinical prostate cancer model.
First Author: Russell Kent Pachynski
Poster
2022 ASCO Annual Meeting
Personalized neoantigen DNA vaccines expand tumor-specific T cells in the periphery which infiltrate the tumor in hepatocellular carcinoma.
First Author: Renzo Perales
Poster
2019 ASCO Annual Meeting
Functional profile and clinical significance of major tumor infiltrating lymphocyte subsets in lung cancer-associated brain metastases.
First Author: Benjamin Y. Lu